Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Explore this paper's citation graph
Summary
The HLA-I genotype of 1535 advanced cancer patients treated with immune checkpoint blockade is determined and Maximal heterozygosity at Hla-I loci improved overall survival after ICB compared with patients who were homozygous for at least one HLA locus.
- Type
- article
- Published
- 2017-12-07
- Cited by
- 1,010
- References
- 86
- OpenAlex
- https://openalex.org/W2774712455
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:206663411
Keywords
Human leukocyte antigen, Loss of heterozygosity, Immunotherapy, Immunology, Cancer immunotherapy
References
- Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.
- Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials
- MHC class I antigens and immune surveillance in transformed cells.
- Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- A Novel Trafficking Signal within the HLA-C Cytoplasmic Tail Allows Regulated Expression upon Differentiation of Macrophages1
- Identification of a new peptide recognized by autologous cytolytic T lymphocytes on a human melanoma.
- Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS.
- Destructive extraction of phospholipids from Escherichia coli membranes by graphene nanosheets.
- An Integrated Tool to Study MHC Region: Accurate SNV Detection and HLA Genes Typing in Human MHC Region Using Targeted High-Throughput Sequencing
- Hierarchical Control of Lymphocyte Survival
- HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage.
- TCR contact residue hydrophobicity is a hallmark of immunogenic CD8+ T cell epitopes
- Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
- Advantage of rare HLA supertype in HIV disease progression
- Identification of the peptide binding motif for HLA-B44, one of the most common HLA-B alleles in the Caucasian population.
- Neoantigens in cancer immunotherapy
- Population Biology of Antigen Presentation by MHC Class I Molecules
- A biological role for the major histocompatibility antigens.
- VMD: visual molecular dynamics.
Cited by
- Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA
- Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy
- Biomarker Discovery in Immunotherapy-treated Melanoma Patients with Imaging Mass Cytometry
- Immunotherapy: HLA genotype: good to be different
- Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens
- Simulation-assisted machine learning
- Enhancing responses to cancer immunotherapy
- HLA Class I Antigen Expression in Conjunctival Melanoma Is Not Associated With PD-L1/PD-1 Status.
- Defective HLA class I antigen processing machinery in cancer
- Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions
- Harnessing and optimizing the interplay between immunotherapy and radiotherapy to improve survival outcomes
- Consolidation systemic treatment after radiochemotherapy for unresectable stage III non-small cell lung cancer.
- Peptide-Binding Groove Contraction Linked to the Lack of T Cell Response: Using Complex Structure and Energy To Identify Neoantigens
- Somatic mutations render human exome and pathogen DNA more similar
- Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma
- Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy
- Update on Tumor Neoantigens and Their Utility: Why It’s Good To Be Different
- The landscape of T cell epitope immunogenicity in sequence space
- Keeping tumors in check: a mechanistic review of clinical response and resistance to immune checkpoint blockade in cancer
- Targeting the cancer mutanome of breast cancer
Related papers
- Loss of Heterozygosity and Microsatellite Instability at Multiple Tumor Suppressor Genes in Gastric Carcinomas
- [Loss of heterozygosity in hepatocellular carcinoma].
- Loss of constitutional heterozygosity in chromosome 10 in human glioblastoma
- Loss of Heterozygosity Associated with Uniparental Disomy in Breast Carcinoma
- [Loss of heterozygosity of tumor suppressor genes at chromosome 3p in transitional cell carcinoma of urinary bladder].
- RER and LOH association with sporadic colorectal cancer in Taiwanese patients.
- Effect of individual gene heterozygosity on blood biochemical parameters in hubei black- boned goats
- Targeting Metabolism to Control Immune Responses in Cancer and Improve Checkpoint Blockade Immunotherapy